GLOW Stack — Research Reference
The GLOW stack extends the Wolverine (BPC-157 + TB-500) healing combination with the addition of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper), a naturally occurring copper tripeptide with extensive published research on collagen synthesis, skin regeneration, hair follicle stimulation, and wound healing. The combination is named for its reported effects on skin appearance, tissue regeneration, and overall vitality.
Stack Overview
| Parameter | Detail |
|---|---|
| Components | BPC-157 + TB-500 + GHK-Cu |
| Mechanisms | Cytoprotection/healing (BPC-157) + angiogenesis/anti-inflammation (TB-500) + collagen synthesis/regeneration (GHK-Cu) |
| Primary reported goal | Comprehensive tissue regeneration, skin quality, hair health, connective tissue repair |
| Category | Healing & Recovery |
Research context: All three compounds have independent research bases. GHK-Cu is one of the more extensively published peptide research areas, with studies dating to the 1970s. The combination is based on complementary mechanisms and anecdotal research accounts — no published clinical trial specifically studies all three together in humans.
Components
| Component | Class | Primary Mechanism | Standard Research Form |
|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | Cytoprotection, tissue repair, NO pathway | 200–500 mcg/day SubQ/IM |
| TB-500 (Thymosin Beta-4) | Thymic peptide | G-actin sequestration, angiogenesis, anti-inflammation | 2–5 mg/week SubQ/IM |
| GHK-Cu | Copper tripeptide | Collagen/elastin synthesis, wound healing, antioxidant, hair | 1–2 mg/day SubQ or topical |
For individual compound profiles, see:
Commonly Reported Protocol
The following information represents commonly reported research ranges from anecdotal accounts. These are not medical recommendations.
Loading Phase (Weeks 1–4)
| Component | Loading Dose | Frequency |
|---|---|---|
| BPC-157 | 250–500 mcg per day | Daily (SubQ or IM) |
| TB-500 | 4–10 mg per week | Once or split twice weekly |
| GHK-Cu | 1–2 mg per day | Daily (SubQ, IM, or topical for skin) |
Maintenance Phase (Weeks 5–16)
| Component | Maintenance Dose | Frequency |
|---|---|---|
| BPC-157 | 200–500 mcg per day | Daily or 5 days/week |
| TB-500 | 2–5 mg per week | Once or split twice weekly |
| GHK-Cu | 1–2 mg per day | Daily or 5 days/week |
Administration Notes
- GHK-Cu can be administered subcutaneously for systemic effects or topically (dissolved in appropriate vehicle) for localised skin and hair effects — anecdotal accounts describe both, and some describe concurrent systemic + topical application
- All three compounds can be administered at the same time or across the day; no interaction between them has been reported
- GHK-Cu is naturally present in human plasma and tissues; it has an excellent tolerability profile in research accounts
Reported Synergies
Foundation + collagen layer: The Wolverine foundation (BPC-157 + TB-500) provides the healing and regenerative base. GHK-Cu adds a collagen and extracellular matrix synthesis component that is more directly skin and connective-tissue-targeted than either BPC-157 or TB-500 in isolation.
Angiogenesis from multiple angles: Both TB-500 and GHK-Cu have been independently associated with angiogenesis promotion in published research — formation of new capillaries that support tissue oxygenation and nutrient delivery. Researchers propose this dual angiogenic stimulus as a synergistic feature of the combination.
Antioxidant support: GHK-Cu is proposed to have significant antioxidant properties via activation of antioxidant gene expression (Nrf2 pathway). This may complement BPC-157’s cytoprotective mechanisms, which include reduction of oxidative stress at the cellular level.
Wound healing completeness: BPC-157 and TB-500 research has focused prominently on musculoskeletal healing. GHK-Cu research has focused prominently on dermal healing, collagen remodelling, and hair follicle support. Together, the three compounds are proposed to cover a broader spectrum of tissue types.
Reported Effects
The following effects have been reported in anecdotal research accounts. This list reflects the research landscape, not confirmed clinical outcomes.
Skin Quality and Appearance
The most distinctive addition from GHK-Cu is its reported effect on skin quality. Anecdotal research accounts frequently describe improved skin texture, density, elasticity, and reduction in fine lines with extended GLOW stack use. GHK-Cu has published research in wound healing and skin rejuvenation, including studies on collagen production and skin remodelling.
Hair Follicle and Hair Quality Effects
GHK-Cu has animal and cell research supporting potential effects on hair follicle cycling and hair density. Anecdotal reports in the research community describe reduced hair shedding and improved hair thickness with GHK-Cu inclusion. This is one of the more distinctly reported effects of the GLOW stack relative to the Wolverine stack.
Connective Tissue and Joint Health
Collagen synthesis stimulation from GHK-Cu complements BPC-157’s effects on tendons and ligaments. Anecdotal accounts describe improved joint comfort and connective tissue resilience with extended use of the full GLOW combination.
Recovery from Injury and Training
The Wolverine stack components contribute the primary recovery effects. GHK-Cu may augment these effects through collagen remodelling support during the tissue repair and remodelling phases.
Overall Vitality
Anecdotal accounts of the GLOW stack frequently describe a general sense of improved vitality, which respondents attribute to the combination of healing, anti-inflammatory, and regenerative effects. This reported effect is difficult to evaluate without controlled data.
Reported Side Effects
Reported side effects in research and anecdotal accounts include the following.
| Side Effect | Frequency Reported |
|---|---|
| Injection site redness or mild pain | Common (any SubQ/IM injection) |
| Skin copper tint at injection site (SubQ GHK-Cu) | Occasionally reported; transient |
| Warmth at injury site | Occasionally reported |
| Fatigue (initial days) | Rarely reported |
The GLOW stack has a minimal reported side effect profile. GHK-Cu is naturally occurring and has an excellent tolerability profile in both research and cosmetic applications. The copper component can produce transient skin discolouration at subcutaneous injection sites.
WADA status: TB-500 is prohibited by WADA and all major anti-doping bodies. Competitive athletes subject to anti-doping rules should review current WADA prohibitions.
Research Context
The GLOW stack is an anecdotal research combination. No clinical trial data specifically investigates BPC-157 + TB-500 + GHK-Cu together. The rationale is mechanistic, supported by independent published research on each component. GHK-Cu is the best-published of the three for skin applications, with research from the 1970s through present day.
GHK-Cu is available commercially in cosmetic skincare formulations — its use in topical products is not regulated as a pharmaceutical. Subcutaneous GHK-Cu is a research compound application.
Frequently Asked Questions
Can GHK-Cu be applied topically instead of injected in this stack? Yes. GHK-Cu is unique among the three components in having an established topical application route, supported by research in wound healing and skin cosmetics. Anecdotal research accounts describe both subcutaneous injection (for systemic effects) and topical application (for skin and hair effects). Some researchers use both routes simultaneously. Topical GHK-Cu does not replace the systemic component in the healing context.
How long does the GLOW stack take to show skin-specific effects? Anecdotal research accounts describe skin quality improvements emerging after 6–12 weeks of consistent use, consistent with the timeline of collagen remodelling (which involves slow turnover of existing collagen). Body composition and healing effects from BPC-157 and TB-500 are typically described within the first 4–8 weeks.
Is the GLOW stack suitable for hair loss? Anecdotal research accounts describe GHK-Cu as the component most associated with potential hair effects, based on its published research in hair follicle biology. The broader GLOW stack is not specifically described as a hair-loss intervention, but anecdotal reports of hair-related benefits in the context of GLOW stack use are common. Published hair research on GHK-Cu does not specifically study it as part of a multi-peptide stack.
Does the GLOW stack require cycling? Anecdotal accounts vary. Some describe continuous use for 16–24 weeks followed by an off period; others describe shorter cycles of 8–12 weeks. The cycling rationale for each component differs: TB-500’s long half-life and WADA considerations drive one approach; GHK-Cu has no established rationale for cycling given its naturally occurring status.
Related Stacks
- Wolverine — BPC-157 + TB-500 — Foundation healing stack (no GHK-Cu)
- KLOW — BPC-157 + TB-500 + GHK-Cu + KPV — GLOW + anti-inflammatory KPV
- CJC-1295 + Ipamorelin — Growth hormone optimisation stack